FDA grants talquetamab (TALVEY™) accelerated approval for relapsed or refractory myelomaAccess, MyelomaAugust 14, 2023
FDA approves elranatamab (ELREXFIO™) for relapsed or refractory myelomaAccess, MyelomaAugust 21, 2023
European Commission approves talquetamab for the treatment of relapsed and refractory myelomaAccess, MyelomaAugust 22, 2023
EMA recommends expansion of melphalan flufenamide (Pepaxti®) marketing authorisationAccess, MyelomaSeptember 18, 2023
EMA CHMP recommends non-renewal of marketing authorisation for Blenrep®Access, MyelomaSeptember 22, 2023
EMA CHMP gives positive recommendation to elranatamab for the treatment of relapsed or refractory myelomaAccess, MPE, MyelomaOctober 13, 2023
Sign up for the MPE webinar on ASH 2023 myeloma and AL amyloidosis highlightsAL amyloidosis, Conferences, MPE, MyelomaDecember 9, 2023
EMA CHMP gives positive opinion on CAR-T treatment idecabtagene vicleucel (Abecma) in earlier lines of therapy for relapsed and refractory myelomaAccess, MyelomaJanuary 30, 2024
